



Divi's Laboratories Limited

Date. 2nd February 2013



The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza
Bandra-Kurla Complex, Bandra (East)
MUMBAI – 400 051
Fax Nos. 022 – 2659 8237 / 38

(by Fax, email & Courier)

Dear Sir,

**Sub: Un-audited financial results for the third quarter ended
31st December 2012 and limited review report –reg**

**Ref: Clause 41 of Listing Agreement - Stock code: DIVISLAB
#**

Pursuant to Clause 41 of the Listing Agreement, please find enclosed un-audited financial results along with the limited review report for the third quarter ended 31st December 2012.

Above un-audited financials were approved and taken on record by the Board of Directors of the Company at their meeting held on Saturday, 2nd February 2013.

The Company proposes release of press note as per the enclosed format. This is for your information and records. Kindly acknowledge the receipt of the same.

Thanking You,

Yours faithfully,

For Divi's Laboratories Limited

P V Lakshmi Rajani
Company Secretary
Encl: a/a

Regd. Off : Divi Towers, 7-1-77/E/1/303, Dharam Karan Road, Ameerpet, Hyderabad - 500 016, INDIA

Tel : 91-40-2378 6300, Fax : 91-40-2378 6460


E-mail : mail@divislaboratories.com, Website : www.divislaboratories.com

DIVI'S LABORATORIES LIMITED

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2012

(Rs.in Lakhs)

	Particulars	STANDALONE					
		Quarter ended			Nine Months ended		Year Ended
		31.12.2012	30.09.2012	31.12.2011	31.12.2012	31.12.2011	31.03.2012
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	(1)	(2)	(3)	(4)	(5)	(6)	(7)
1	Income from operations	53333	47260	41658	147434	113153	183949
	(a) Net Sales/Income from operations (Net of Excise Duty)						
	(b) Other Operating Income	103	114	82	327	197	544
	Total Income from operations (net)	53436	47374	41740	147761	113350	184493
2	Expenses						
	a. Cost of materials consumed	26080	23131	20476	66468	53407	77177
	b. Purchases of stock-in-trade	14	0	0	14	0	10
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(3972)	(6978)	(4243)	(12124)	(8337)	(1066)
	d. Employee benefits expense	4552	4337	3590	13734	10123	14516
	e. Depreciation and amortization expense	2036	1879	1620	5663	4540	6203
	f. Other Expenses	8531	10385	6800	23707	17276	24369
	Total Expenses	37241	32754	28243	97462	77009	121209
3	Profit from Operations before Other Income, Finance Costs & Exceptional Items (1-2)	16195	14620	13497	50299	36341	63284
4	Other Income	2232	847	2554	5067	6140	6576
5	Profit from ordinary activities before finance costs & exceptional Items (3+4)	18427	15467	16051	55366	42481	69860
6	Finance Costs	44	31	11	116	132	374
7	Profit from ordinary activities after finance costs but before exceptional Items (5-6)	18383	15436	16040	55250	42349	69486
8	Exceptional items	0	0	0	0	0	0
9	Profit from ordinary activities before Tax (7-8)	18383	15436	16040	55250	42349	69486
10	Tax Expense	3959	3639	3785	12291	9230	14889
11	Net Profit from ordinary activities after Tax (9-10)	14424	11797	12255	42959	33119	54597
12	Extra-ordinary items (net of tax expense)	0	0	0	0	0	0
13	Net Profit (+)/Loss(-) for the period (11-12)	14424	11797	12255	42959	33119	54597
14	Share of profit / (loss) of associates	0	0	0	0	0	0
15	Minority Interest	0	0	0	0	0	0



16	Net Profit (+)/Loss(-) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)	14424	11797	12255	42959	33119	54597
17	Paid-up Equity Share Capital (Face Value : Rs.2 per share)	2655	2655	2654	2655	2654	2655
18	Reserves excluding revaluation reserves as per balance sheet of previous accounting year						214825
19.i	Earnings per Share (before extraordinary items) (of Rs.2/- each) (not annualized):						
	a) Basic	10.86	8.89	9.24	32.36	24.97	41.15
	b) Diluted	10.86	8.89	9.24	32.36	24.97	41.15
19.ii	Earnings per Share (after extraordinary items) (of Rs.2/- each) (not annualized):						
	a) Basic	10.86	8.89	9.24	32.36	24.97	41.15
	b) Diluted	10.86	8.89	9.24	32.36	24.97	41.15

A	PARTICULARS OF SHAREHOLDING						
1	Public shareholding - No. of shares - Percentage of shareholding	63512190 47.85%	63512190 47.85%	63481010 47.84%	63512190 47.85%	63481010 47.84%	63512190 47.85%
2	Promoters and promoter group shareholding a) pledged / encumbered b) non-encumbered: - No. of shares - Percentage of shares (as a % of the total shareholding of the promoter group) - Percentage of shares (as a % of the total share capital of the company)	Nil 69222100 100% 52.15%	Nil 69222100 100% 52.15%	Nil 69222100 100% 52.16%	Nil 69222100 100% 52.15%	Nil 69222100 100% 52.16%	Nil 69222100 100% 52.15%


	Particulars	Quarter ended 31-12-2012
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	17
	Disposed off during the quarter	17
	Remaining unresolved at the end of the quarter	Nil

NOTES:


- The above results for the period ended 31st December 2012, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 2nd February, 2013 and were subjected to 'limited review' by the Auditors.
- The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 notified under the Companies Act, 1956.

3. As per Clause 41 of the listing agreement, the company has opted to publish quarterly unaudited Standalone Results and to publish consolidated results at the year end.
4. Accounts have been reclassified as per the revised Schedule VI to Companies Act, 1956. Directors' Remuneration which was included earlier under Other Expenditure has now been included under Employee Cost.
5. Figures for the previous year/periods have also been regrouped or recasted, wherever necessary.

Place: Hyderabad
Date: 02-02-2013



for Divi's Laboratories Limited


Dr. Murali K. Divi
Chairman & Managing Director

DIVI'S LABORATORIES LIMITED
Hyderabad



PRESS RELEASE dated 2nd February, 2013

Divi's Labs earns an Income of Rs.534 crores in Q3 of FY13

Divi's Laboratories has earned a total income of Rs.534 crores on a stand-alone basis for the quarter ended 31st December, 2012 as against an income of Rs. 417 crores during the corresponding quarter last year. Profit before Tax (PBT) for the quarter came to Rs.184 crores as against a PBT of Rs. 160 crores for the corresponding previous quarter. Profit after Tax (PAT) for the current quarter came to Rs.144 crores as against Rs. 123 crores during the corresponding previous quarter.

Power continues to be critical in Andhra Pradesh due to severe power shortage in the State and the company continues to rely on purchased power at higher cost. Forex gain for the quarter amounted to Rs.16 crores while there was a forex loss of Rs.21 crores during the quarter ending 30th September, 2012.

For the 9-month period ended 31st December, 2012, the company earned a total income of Rs.1478 crores as compared to Rs.1134 crores during the corresponding 9-month period of last year. PBT for the current 9-month period came to Rs.553 crores as against a PBT of Rs.423 crores for the previous period. PAT for the current 9-months is Rs.430 crores as against Rs.331 crores for the previous period.





P.V.R.K. Nageswara Rao & Co.,
Chartered Accountants

LIMITED REVIEW REPORT

We have reviewed the accompanying statement of unaudited financial results of **DIVT'S LABORATORIES LIMITED** for the period ended **31st December, 2012** except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors / Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P.V.R.K. NAGESWARA RAO & Co.,
Chartered Accountants

Firm's Registration Number: 002283S

HYDERABAD
02.02.2013


N. ANKA RAO

Partner

Membership Number: 23939

